ARMATA PHARMACEUTICALS, INC. Proceeds from Short-term Debt
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Proceeds from Short-term Debt of $29.23 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromShortTermDebt · last filed 2023-08-14
- ARMATA PHARMACEUTICALS, INC. proceeds from short-term debt for the quarter ending 2023-06-30 was -$368.00K.
- ARMATA PHARMACEUTICALS, INC. proceeds from short-term debt for the quarter ending 2023-03-31 was $29.59M.
| Period end | Proceeds from Short-term Debt 3 month | Proceeds from Short-term Debt 6 month |
|---|---|---|
| 2023-06-30 | -$368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $29.23M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $29.59M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |